Humanwell Healthcare Group Co Ltd banner

Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 18.71 CNY -0.48% Market Closed
Market Cap: ¥30.5B

Humanwell Healthcare Group Co Ltd
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Humanwell Healthcare Group Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Humanwell Healthcare Group Co Ltd
SSE:600079
Total Equity
¥18.9B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
9%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Equity
¥35.4B
CAGR 3-Years
16%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Equity
¥61.3B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
20%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Equity
¥40B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
12%
Zhejiang Nhu Co Ltd
SZSE:002001
Total Equity
¥32.8B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
17%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Equity
¥3.9B
CAGR 3-Years
127%
CAGR 5-Years
56%
CAGR 10-Years
N/A
No Stocks Found

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
30.5B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
30.38 CNY
Undervaluation 38%
Intrinsic Value
Price ¥18.71

See Also

What is Humanwell Healthcare Group Co Ltd's Total Equity?
Total Equity
18.9B CNY

Based on the financial report for Dec 31, 2025, Humanwell Healthcare Group Co Ltd's Total Equity amounts to 18.9B CNY.

What is Humanwell Healthcare Group Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
9%

Over the last year, the Total Equity growth was 7%. The average annual Total Equity growth rates for Humanwell Healthcare Group Co Ltd have been 8% over the past three years , 12% over the past five years , and 9% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett